Dr. Postow on OS Results of CheckMate-069 Study

Michael Postow, MD
Published: Monday, Apr 18, 2016



Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the overall survival (OS) results of the CheckMate-069 study, which investigated the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The first OS results ofthe study, which were presented at the 2016 AACR Annual Meeting, demonstrated a 42% improvement in OS with the combination versus ipilimumab monotherapy for patients with advanced melanoma in a 2-year assessment. The median OS among patients was not been reached with the combination and was 24.8 months with ipilimumab monotherapy. In the overall study population, the 2-year OS rate was 64% with the combination compared with 54% for ipilimumab alone. The median OS at 2 years in patients randomized to either the combination or monotherapy has not been reached. 

The median progression-free survival and median duration of response in BRAF wild-type patients, as well as all randomized patients, has also not yet been reached, Postow explains. 

<<< View more from the 2016 AACR Annual Meeting



Michael Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the overall survival (OS) results of the CheckMate-069 study, which investigated the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with melanoma.

The first OS results ofthe study, which were presented at the 2016 AACR Annual Meeting, demonstrated a 42% improvement in OS with the combination versus ipilimumab monotherapy for patients with advanced melanoma in a 2-year assessment. The median OS among patients was not been reached with the combination and was 24.8 months with ipilimumab monotherapy. In the overall study population, the 2-year OS rate was 64% with the combination compared with 54% for ipilimumab alone. The median OS at 2 years in patients randomized to either the combination or monotherapy has not been reached. 

The median progression-free survival and median duration of response in BRAF wild-type patients, as well as all randomized patients, has also not yet been reached, Postow explains. 

<<< View more from the 2016 AACR Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x